

# Kimberly-Clark Announces Second Quarter 2021 Results

July 23, 2021

DALLAS, July 23, 2021 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE: KMB) today reported second quarter 2021 results.

#### **Executive Summary**

- Second quarter 2021 net sales of \$4.7 billion increased 2 percent compared to the year-ago period, with an organic sales decline of 3 percent.
- Diluted net income per share for the second quarter was \$1.19 in 2021 and \$1.99 in 2020.
- Second quarter adjusted earnings per share were \$1.47 in 2021 compared to \$2.20 in 2020. Adjusted earnings per share exclude certain items described later in this news release.
- Diluted net income per share for 2021 is anticipated to be \$6.00 to \$6.50.
- The company is now targeting full-year 2021 organic sales decline of 0 to 2 percent and adjusted earnings per share of \$6.65 to \$6.90. The prior outlook was for organic sales growth of 0 to 1 percent and adjusted earnings per share of \$7.30 to \$7.55. The updated earnings outlook reflects significantly higher input cost inflation and lower sales volumes, partially offset by additional cost savings and reduced discretionary spending.

Chairman and Chief Executive Officer Mike Hsu said, "Our second quarter reflects continued pandemic-driven volatility. We are facing significantly higher input costs and a reversal in consumer tissue volumes from record growth in the year ago period as consumers and retailers in North America continued to reduce home and retail inventory. While we look forward to a return to a more normalized environment, we have moved decisively to take pricing actions to mitigate inflationary headwinds and continue to prudently manage costs. We remain confident in our strategy and in our fundamental brand performance. Our personal care business is performing well, and we continue to improve our market positions in key markets and realize robust growth across Developing and Emerging Markets."

Hsu continued, "We will continue to execute K-C Strategy 2022. While our updated outlook reflects a more challenging near-term environment, we are taking appropriate actions and remain confident in our strategies to create long-term shareholder value."

## Second Quarter 2021 Operating Results

Sales of \$4.7 billion in the second quarter of 2021 increased 2 percent versus the prior year. Changes in foreign currency exchange rates increased sales 3 percent and the net impact of the Softex Indonesia acquisition and exited businesses in conjunction with the 2018 Global Restructuring Program increased sales 2 percent. Organic sales decreased 3 percent as volumes declined 4 percent while the combined impact of changes in net selling prices and product mix increased sales approximately 1 percent.

In North America, organic sales decreased 11 percent in consumer products and 4 percent in K-C Professional. Volumes in North America, particularly consumer tissue, were negatively impacted by consumer and retailer destocking following the stock up that occurred in prior periods related to the global outbreak of COVID-19. Outside North America, organic sales were up 9 percent in developing and emerging (D&E) markets and up 1 percent in developed markets.

Second quarter operating profit was \$613 million in 2021 and \$925 million in 2020. Results in both periods include charges related to the 2018 Global Restructuring Program. Second quarter adjusted operating profit was \$676 million in 2021 and \$1,012 million in 2020. Results were impacted by lower sales volumes and \$345 million of higher input costs, driven by pulp, other materials and distribution costs. Other manufacturing costs were higher, including inefficiencies from lower production volumes. Results benefited from higher net selling prices, \$115 million of cost savings from the company's FORCE (Focused On Reducing Costs Everywhere) program, \$30 million of cost savings from the 2018 Global Restructuring Program and lower marketing, research and general expense.

The second quarter effective tax rate was 22.8 percent in 2021 and 23.2 percent in 2020. The second quarter adjusted effective tax rate was 22.5 percent in 2021 and 22.7 percent in 2020. Kimberly-Clark's share of net income of equity companies in the second quarter was \$28 million in 2021 and \$35 million in 2020.

#### **Cash Flow and Balance Sheet**

Cash provided by operations in the second quarter was \$565 million in 2021 and an all-time record of \$1,579 million in 2020. The decrease was driven by higher working capital, lower earnings and higher tax payments. Capital spending for the second quarter was \$201 million in 2021 and \$284 million in 2020.

Second quarter 2021 share repurchases were 1.2 million shares at a cost of \$161 million. The company now plans for full-year repurchases of \$400 to \$450 million, below the original target range of \$650 to \$750 million. Total debt was \$9.1 billion at June 30, 2021 and \$8.4 billion at the end of 2020.

# Second Quarter 2021 Business Segment Results

## Personal Care Segment

Second quarter sales of \$2.5 billion increased 13 percent. The net impact of the Softex Indonesia acquisition and exited businesses in conjunction with the 2018 Global Restructuring Program increased sales 4 percent while changes in currency rates increased sales 3 percent. Volumes increased 4 percent while product mix improved 2 percent. Second quarter operating profit of \$454 million decreased 13 percent. Results were impacted by input cost inflation and higher other manufacturing cost increases while the comparison benefited from organic sales growth and cost savings.

Sales in North America increased 2 percent. Product mix improved 2 percent, driven by baby and child care, and changes in currency rates increased sales 1 percent. Exited business related to the 2018 Global Restructuring program reduced sales 1 percent.

Sales in D&E markets increased 24 percent. The Softex Indonesia acquisition increased sales by 14 percent while changes in currency rates increased sales 2 percent. Volumes rose 6 percent and the combined impact of changes in net selling prices and product mix increased sales 2 percent. Organic sales increased in Argentina, Brazil, China, India and throughout the Middle East, Africa, Eastern Europe region but declined in ASEAN and most of the rest of Latin America.

Sales in developed markets outside North America (Australia, South Korea and Western/Central Europe) increased 26 percent. Changes in currency rates increased sales 14 percent and volumes rose 12 percent.

#### Consumer Tissue Segment

Second quarter sales of \$1.4 billion decreased 13 percent. Volumes declined 15 percent while changes in currency rates increased sales about 3 percent. The volume decline was driven by reduced shipments in North America, reflecting category softness as retailers reduce inventory and consumers reduce at home usage and pantry levels following the stock up that occurred in prior periods related to the global outbreak of COVID-19. Second quarter operating profit of \$196 million decreased 54 percent. The comparison was impacted by lower organic sales, higher input costs and other manufacturing cost increases, including inefficiencies from lower production volumes. Results benefited from cost savings, lower advertising spending and favorable currency effects.

Sales in North America decreased 26 percent. Volumes fell 27 percent and product mix was down 2 percent, while net selling prices improved 2 percent.

Sales in D&E markets increased 9 percent including a 3 point favorable impact from changes in currency rates. Volumes rose 3 percent and product mix improved 1 percent, while net selling prices were down 2 percent. The Softex Indonesia acquisition increased sales 4 percent.

Sales in developed markets outside North America increased 1 percent, including a 10 percent benefit from changes in currency rates. Net selling prices were down 6 percent, compared to very low promotion levels in the year-ago period, and volumes were down 1 percent. Exited businesses related to the 2018 Global Restructuring program reduced sales 2 percent.

#### K-C Professional (KCP) Segment

Second quarter sales of \$0.8 billion increased 6 percent. Net selling prices increased approximately 5 percent, product mix improved 1 percent and changes in currency rates increased sales 3 percent. Volumes declined 4 percent. Second quarter operating profit of \$110 million decreased 29 percent. The comparison was impacted by lower volumes and higher input costs. Results benefited from increased net selling prices and cost savings.

Sales in North America decreased 3 percent. Volumes were down 11 percent, while net selling prices rose approximately 6 percent and product mix improved 2 percent. Sales were down mid-teens in washroom products and wipers while sales increased double-digits in safety and other products, mostly due to higher net selling prices and favorable product mix.

Sales in D&E markets increased 31 percent including a 3 point benefit from changes in currency rates. Volumes rose 24 percent, compared to a soft year-ago period, while net selling prices increased 5 percent.

Sales in developed markets outside North America were up 13 percent including an 11 percent benefit from changes in currency rates. Net selling prices increased 5 percent while volumes decreased approximately 2 percent.

# Year-To-Date Results

For the first six months of 2021, sales of \$9.5 billion decreased 2 percent. Organic sales decreased 5 percent, as volumes declined 7 percent and net selling prices and product mix each improved 1 percent. Changes in foreign currency exchange rates increased sales by approximately 2 percent and the net impact of the Softex Indonesia acquisition and business exits in conjunction with the 2018 Global Restructuring Program increased sales 2 percent.

Year-to-date operating profit was \$1,383 million in 2021 and \$1,829 million in 2020. Results in both periods include charges related to the 2018 Global Restructuring Program. Year-to-date adjusted operating profit was \$1,480 million in 2021 and \$2,009 million in 2020. Results were impacted by lower sales volumes, higher input costs and elevated other manufacturing costs. Results benefited from higher net selling prices, \$180 million of FORCE savings and \$70 million of cost savings from the 2018 Global Restructuring Program.

Through six months, diluted net income per share was \$2.92 in 2021 and \$3.92 in 2020. Year-to-date adjusted earnings per share were \$3.27 in 2021 and \$4.34 in 2020.

#### 2018 Global Restructuring Program

In January 2018, Kimberly-Clark initiated the 2018 Global Restructuring Program in order to reduce the company's structural cost base and enhance the company's flexibility to invest in its brands, growth initiatives and capabilities critical to delivering future growth. As part of the program, Kimberly-Clark expects to exit or divest some low-margin businesses that generate about 1 percent of company net sales.

The restructuring is expected to be completed in 2021. Total restructuring charges are anticipated to be \$2,000 to \$2,100 million pre-tax (\$1,490 to \$1,570 million after tax). The company expects the program will generate annual pre-tax cost savings of \$540 to \$560 million by the end of 2021. Through the second quarter of 2021, the company has incurred cumulative restructuring charges of \$1,974 million pre-tax (\$1,474 million after tax) and generated cumulative savings of \$495 million.

## 2021 Outlook and Key Planning Assumptions

The company updated the following key planning and guidance assumptions for full-year 2021:

- Net sales increase 1 to 4 percent (prior assumption 3 to 5 percent).
  - o Organic sales decline 0 to 2 percent (prior target 0 to 1 percent increase).
  - Foreign currency exchange rates favorable between 1 and 2 percent (no change).
  - Softex Indonesia acquisition expected to increase sales 2 percent while exited businesses in conjunction with the 2018 Global Restructuring Program anticipated to reduce sales slightly (no change).
- Adjusted operating profit expected to decline 11 to 14 percent year-on-year (prior assumption decline of 3 to 6 percent).
  - Key cost inputs expected to increase \$1,200 to \$1,300 million (previous estimate \$900 to \$1,050 million). The increased estimate is driven by polymer-based materials and pulp.
  - Cost savings of \$520 to \$560 million, including \$400 to \$420 million from the FORCE program and \$120 to \$140 million from the 2018 Global Restructuring Program. The prior estimate was for total savings of \$460 to \$520 million.
- Net income from equity companies similar, to down somewhat, year-on-year (prior outlook similar, to up somewhat).
- Adjusted earnings per share of \$6.65 to \$6.90 (prior outlook \$7.30 to \$7.55).
- Capital spending of \$1,100 to \$1,200 million (prior outlook \$1,200 to \$1,300 million).
- Share repurchase of \$400 to \$450 million (prior outlook \$650 to \$750 million).

# Prepared Management Remarks and Live Question and Answer Webcast

At approximately 7:00 a.m. (Central time) on July 23, 2021, the company will post management remarks (in PDF format) regarding its second quarter 2021 results and full-year 2021 outlook at <a href="https://www.kimberly-clark.com">www.kimberly-clark.com</a>. At 9:00 am (Central time) on July 23, 2021, the company will host a live question and answer session with investors and analysts. Stockholders and others are invited to listen to the live broadcast or a playback, which will be accessible on the company's website at <a href="https://www.kimberly-clark.com">www.kimberly-clark.com</a>.

#### **Non-GAAP Financial Measures**

This news release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:

- · Adjusted earnings and earnings per share
- · Adjusted gross and operating profit
- · Adjusted effective tax rate

These non-GAAP financial measures exclude the charges for the 2018 Global Restructuring Program (mentioned elsewhere in this release) for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures.

The company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the company's Board of Directors use adjusted earnings, adjusted earnings per share and adjusted gross and operating profit to (a) evaluate the company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of our ongoing business operations.

Additionally, the Management Development and Compensation Committee of the company's Board of Directors has used certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the company's adjusted earnings per share and improvement in the company's adjusted return on invested capital determined by excluding certain of the adjustments that are used in calculating these non-GAAP financial measures.

This news release includes information regarding organic sales growth, which describes the impact of changes in volume, net selling prices and product mix on net sales. Changes in foreign currency exchange rates, acquisitions and exited businesses also impact the year-over-year change in net sales.

#### **About Kimberly-Clark**

Kimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create products that help individuals experience more of what's important to them. Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Neve, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 80 countries. We use sustainable practices that support a healthy planet, build strong communities, and ensure our business thrives for decades to come. To keep up with the latest news and to learn more about the company's nearly 150-year history of innovation, visit kimberly-clark.com.

Copies of Kimberly-Clark's Annual Report to Stockholders and its proxy statements and other SEC filings, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, are made available free of charge on the company's Web site on the same day they are filed with the SEC. To view these filings, visit the Investors section of the company's Web site.

As more fully described in Kimberly-Clark's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, the company has been actively monitoring the COVID-19 situation and its impact globally. The impact of COVID-19 and measures to prevent its spread are affecting our business in a number of ways. We have experienced increased volatility in demand for some of our products as consumers adapt to the evolving environment. We have also experienced incidents of supply chain disruption and increased currency and commodity volatility. We expect the ultimate significance of the impact on our financial and operational results will be dictated by the length of time that such circumstances continue, which will depend on the currently unknowable extent and duration of the COVID-19 pandemic and governmental and public actions taken in response. COVID-19 also makes it more challenging for management to estimate future business performance, particularly over the near term.

Certain matters contained in this news release concerning the outlook, anticipated financial and operating results, raw material, energy and other input costs, anticipated currency rates and exchange risks, including in Argentina, net income from equity companies, sources and uses of cash, the effective tax rate, the anticipated cost savings from the company's FORCE program, charges and savings from the 2018 Global Restructuring Program, growth initiatives, product innovations, contingencies and anticipated transactions of the company constitute forward-looking statements and are based upon management's expectations and beliefs concerning future events impacting the company. In addition, many factors outside our control, including pandemics (including the ongoing COVID-19 outbreak and the related responses of governments, consumers, customers, suppliers and employees), epidemics, the prices and availability of our raw materials, supply chain disruptions due to COVID-19, changes in customer preferences (including consumer tissue destocking following a COVID-19 related stock up in 2020), severe weather conditions or government trade or similar regulatory actions, potential competitive pressures on selling prices for our products, energy costs, failure to realize the expected benefits or synergies from the Softex Indonesia acquisition, fluctuations in foreign currency exchange rates, our ability to maintain key customer relationships, as well as general economic and political conditions globally and in the markets in which we do business, could affect the realization of these estimates.

There can be no assurance that these future events will occur as anticipated or that the company's results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them. For a description of certain factors that could cause the company's future results to differ from those expressed in any such forward-looking statements, see Item 1A entitled "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2020.

# KIMBERLY-CLARK CORPORATION CONSOLIDATED INCOME STATEMENTS

(Millions, except per share amounts)

	Thi	ree Months	Ended	June 30	
		2021		2020	Change
Net Sales	\$	4,722	\$	4,612	+2 %
Cost of products sold		3,242		2,835	+14 %
Gross Profit		1,480		1,777	-17 %
Marketing, research and general expenses		854		844	+1 %
Other (income) and expense, net		13		8	+63 %
Operating Profit		613		925	-34 %
Nonoperating expense		(55)		(6)	+817 %
Interest income		2		2	_
Interest expense		(65)		(65)	_
Income Before Income Taxes and Equity Interests		495		856	-42 %
Provision for income taxes		(113)		(199)	-43 %
Income Before Equity Interests		382		657	-42 %
Share of net income of equity companies		28		35	-20 %
Net Income		410		692	-41 %
Net income attributable to noncontrolling interests		(6)		(11)	-45 %
Net Income Attributable to Kimberly-Clark Corporation	\$	404	\$	681	-41 %
Per Share Basis					
Net Income Attributable to Kimberly-Clark Corporation	1				
Basic	\$	1.20	\$	2.00	-40 %
Diluted	\$	1.19	\$	1.99	-40 %
Cash Dividends Declared	\$	1.14	\$	1.07	+7 %

Common Shares Outstanding	June	30
<u>-</u>	2021	2020
Outstanding shares as of	336.9	341.0
Average diluted shares for three months ended	338.3	341.9

Unaudited

# KIMBERLY-CLARK CORPORATION CONSOLIDATED INCOME STATEMENTS (Millions, except per share amounts)

	Six Months		
	2021	 2020	Change
Net Sales	\$ 9,465	\$ 9,621	-2 %
Cost of products sold	6,396	 6,053	+6 %
Gross Profit	3,069	3,568	-14 %
Marketing, research and general expenses	1,669	1,717	-3 %
Other (income) and expense, net	17	 22	-23 %
Operating Profit	1,383	1,829	-24 %
Nonoperating expense	(61)	(17)	+259 %
Interest income	3	4	-25 %

Interest expense	(128)	(126)	+2 %
Income Before Income Taxes and Equity Interests	1,197	1,690	-29 %
Provision for income taxes	(260)	(396)	-34 %
Income Before Equity Interests	937	1,294	-28 %
Share of net income of equity companies	67	73	-8 %
Net Income	1,004	1,367	-27 %
Net income attributable to noncontrolling interests	(16)	(26)	-38 %
Net Income Attributable to Kimberly-Clark Corporation	\$ 988	\$ 1,341	-26 %
Per Share Basis			
Net Income Attributable to Kimberly-Clark Corporation			
Basic	\$ 2.92	\$ 3.93	-26 %
Diluted	\$ 2.92	\$ 3.92	-26 %
Cash Dividends Declared	\$ 2.28	\$ 2.14	+7 %
Common Shares Outstanding	Jur	ne 30	
	2021	2020	
Average diluted shares for six months ended	338.8	342.3	

Unaudited

# KIMBERLY-CLARK CORPORATION NON-GAAP RECONCILIATIONS (Millions, except per share amounts)

Three Months Ended June 30, 2021 2018 Global As Restructuring Adjusted Non-GAAP Reported Program 3,242 3,217 Cost of products sold \$ 25 1,480 Gross Profit (25) 1,505 Marketing, research and general expenses 854 30 824 Other (income) and expense, net 13 5 Operating Profit 613 (63)676 Nonoperating expense (55)(56)Provision for income taxes (138)(113) 25 Effective tax rate 22.8 % 22.5 % Net Income Attributable to Kimberly-Clark Corporation 404 (94)498 Diluted Earnings per Share(a) 1.19 1.47 (0.28)

		Three M	onths En	ded June	<u>30, 20</u>	20	
			2018	Global		As	
		As	Restru	cturing	Adjusted		
	Re	eported	Prog	gram	No	n-GAAP	
Cost of products sold	\$	2,835	\$	60	\$	2,775	
Gross Profit		1,777		(60)		1,837	
Marketing, research and general expenses		844		27		817	
Operating Profit		925		(87)		1,012	
Provision for income taxes		(199)		15		(214)	
Effective tax rate		23.2 %		_		22.7 %	
Share of net income of equity companies		35		(1)		36	
Net income attributable to noncontrolling interests		(11)		1		(12)	
Net Income Attributable to Kimberly-Clark Corporation		681		(72)		753	
Diluted Earnings per Share <sup>(a)</sup>		1.99		(0.21)		2.20	

<sup>(</sup>a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.

Unaudited

KIMBERLY-CLARK CORPORATION NON-GAAP RECONCILIATIONS (Millions, except per share amounts)

		Six Mo	nths End	ded June 3	0, 202	1
			2018	Global		As
		As	Restru	ucturing	Α	djusted
	Re	eported	Pro	gram	No	n-GAAP
Cost of products sold	\$	6,396	\$	50	\$	6,346
Gross Profit		3,069		(50)		3,119
Marketing, research and general expenses		1,669		39		1,630
Other (income) and expense, net		17		8		9
Operating Profit		1,383		(97)		1,480
Nonoperating expense		(61)		(56)		(5)
Provision for income taxes		(260)		32		(292)
Effective tax rate		21.7 %		_		21.6 %
Net income attributable to noncontrolling interests		(16)		1		(17)
Net Income Attributable to Kimberly-Clark Corporation		988		(120)		1,108
Diluted Earnings per Share <sup>(a)</sup>		2.92		(0.35)		3.27

		Six Mo	nths End	ded June 3	0, 202	0
			2018	Global		As
		As	Restru	ucturing	A	djusted
	R	eported	Pro	gram	No	n-GAAP
Cost of products sold	\$	6,053	\$	130	\$	5,923
Gross profit		3,568		(130)		3,698
Marketing, research and general expenses		1,717		50		1,667
Operating profit		1,829		(180)		2,009
Provision for income taxes		(396)		33		(429)
Effective tax rate		23.4 %		_		22.9 %
Share of net income of equity companies		73		(1)		74
Net income attributable to noncontrolling interests		(26)		2		(28)
Net income attributable to Kimberly-Clark Corporation		1,341		(146)		1,487
Diluted Earnings per Share <sup>(a)</sup>		3.92		(0.43)		4.34

(a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.

Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. The company compensates for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures.

Unaudited

# KIMBERLY-CLARK CORPORATION CONSOLIDATED BALANCE SHEETS (Millions)

	June	30, 2021	December 31, 202		
ASSETS		_			
Current Assets					
Cash and cash equivalents	\$	306	\$	303	
Accounts receivable, net		2,340		2,235	
Inventories		2,110		1,903	
Other current assets		816		733	
Total Current Assets		5,572		5,174	
Property, Plant and Equipment, Net		8,018		8,042	
Investments in Equity Companies		350		300	
Goodwill		1,834		1,895	
Other Intangible Assets, Net		803		832	
Other Assets		1,250		1,280	
TOTAL ASSETS	\$	17,827	\$	17,523	
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current Liabilities					
Debt payable within one year	\$	1,493	\$	486	
Trade accounts payable		3,337		3,336	
Accrued expenses and other current liabilities		2,037		2,262	
Dividends payable		377		359	
Total Current Liabilities		7,244		6,443	

Long-Term Debt	7,591	7,878
Noncurrent Employee Benefits	875	864
Deferred Income Taxes	665	723
Other Liabilities	666	718
Redeemable Preferred Securities of Subsidiaries	28	28
Stockholders' Equity		
Kimberly-Clark Corporation	524	626
Noncontrolling Interests	234	243
Total Stockholders' Equity	758	869
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 17,827	\$ 17,523

2021 Data is Unaudited

# KIMBERLY-CLARK CORPORATION CONSOLIDATED CASH FLOW STATEMENTS (Millions)

Operating Activities         2021         2020         2021         2020           Net income         \$410         \$692         \$1,004         \$1,367           Depreciation and amortization         189         201         378         414           Asset impairments         —         —         3         —           Stock-based compensation         20         39         42         54           Deferred income taxes         (39)         21         (74)         12           Net (gains) losses on asset dispositions         11         6         15         13           Equity companies' earnings (in excess of) less than dividends paid         6         (9)         322         (47)           Operating working capital         (95)         634         (495)         480           Post tetirement benefits         51         (1)         36         (15)           Other         12         (4)         9         (5)           Cash Provided by Operations         565         1,579         866         2,283           Investments in depositions of property         30         4         30         5           Capital spending         (201)         (284)         (499)         (636)			Months Ended June 30	Six Months Ended June 30		
Net income						
Depreciation and amortization	Operating Activities					
Asset impairments	Net income	\$ 410	\$ 692	\$ 1,004	\$ 1,367	
Stock-based compensation         20         39         42         54           Deferred income taxes         (39)         21         (74)         12           Net (gains) losses on asset dispositions         11         6         15         13           Equity companies' earnings (in excess of) less than dividends paid         6         (9)         (32)         (47)           Operating working capital         (95)         634         (495)         490           Postretirement benefits         51         (1)         36         (15)           Other         12         (4)         9         (5)           Cash Provided by Operations         565         1,579         886         2,283           Investing Activities         201         (284)         (499)         (636)           Proceeds from dispositions of property         30         4         30         5           Investments in time deposits         (292)         (218)         (451)         (323)           Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (389)         (365)         (748)	Depreciation and amortization	189	201	378	414	
Deferred income taxes   (39)	Asset impairments	_	_	3	_	
Net (gains) losses on asset dispositions   11	Stock-based compensation	20	39	42	54	
Net (gains) losses on asset dispositions	Deferred income taxes	(39)	21	(74)	12	
Equity companies' earnings (in excess of) less than dividends paid Operating working capital Operating working capital (95)         634 (495)         490 (495)         490 (15)	Net (gains) losses on asset dispositions		6		13	
Operating working capital         (95)         634         (495)         490           Postretirement benefits         51         (1)         36         (15)           Other         12         (4)         9         (5)           Cash Provided by Operations         565         1,579         886         2,283           Investing Activities         2         1,579         886         2,283           Investing Activities         2         2011         (284)         (499)         (636)           Proceeds from dispositions of property         30         4         30         5           Investments in time deposits         (292)         (218)         (451)         (323)           Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         (242)         (331)         (487)         (690)           Financing Activities         (243)         (385)         960         (667)           Cash dividends paid         (389)         (365)         (748)         (722)		6	(9)	(32)	(47)	
Other         12         (4)         9         (5)           Cash Provided by Operations         565         1,579         886         2,283           Investing Activities         Investing Activities           Capital spending         (201)         (284)         (499)         (636)           Proceeds from dispositions of property         30         4         30         5           Investments in time deposits         (292)         (218)         (451)         (323)           Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         Stancing Activities           Cash dividends paid         (389)         (365)         (748)         (722)           Cash dividends paid         (389)         (365)         (748)         (722)           Cash dividends paid         (389)         (365)         (748)         (722)           Debt repayments         216         (385)         960         (667)           Debt repayments         -         -         - <td></td> <td>(95)</td> <td>634</td> <td>(495)</td> <td>490</td>		(95)	634	(495)	490	
Cash Provided by Operations         565         1,579         886         2,283           Investing Activities         Capital spending         (201)         (284)         (499)         (636)           Proceeds from dispositions of property         30         4         30         5           Investments in time deposits         (292)         (218)         (451)         (323)           Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities           Cash dividends paid         (389)         (365)         (748)         (722)           Change in short-term debt         216         (385)         960         (667)           Debt proceeds         —         —         5         1,241           Debt repayments         —         —         5         1,241           Debt repayments         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common	Postretirement benefits	51	(1)	36	(15)	
Capital spending	Other	12	(4)	9	(5)	
Capital spending	Cash Provided by Operations	565	1,579	886	2,283	
Proceeds from dispositions of property         30         4         30         5           Investments in time deposits         (292)         (218)         (451)         (323)           Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         (242)         (331)         (487)         (690)           Financing Activities         (389)         (365)         (748)         (722)           Cash dividends paid         (389)         (365)         (748)         (722)           Change in short-term debt         216         (385)         960         (667)           Debt proceeds         —         —         —         5         1,241           Debt repayments         —         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common stock for the treasury         (162)         (49)         (331)         (263)           Other         (24)         (15)	· · · · · · · · · · · · · · · · · · ·					
Proceeds from dispositions of property         30         4         30         5           Investments in time deposits         (292)         (218)         (451)         (323)           Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         (242)         (331)         (487)         (690)           Financing Activities         (389)         (365)         (748)         (722)           Cash dividends paid         (389)         (365)         (748)         (722)           Change in short-term debt         216         (385)         960         (667)           Debt proceeds         —         —         —         5         1,241           Debt repayments         —         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common stock for the treasury         (162)         (49)         (331)         (263)           Other         (24)         (15)	Capital spending	(201)	(284)	(499)	(636)	
Maturities of time deposits         226         158         433         254           Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         Cash dividends paid         (389)         (365)         (748)         (722)           Change in short-term debt         216         (385)         960         (667)           Debt proceeds         —         —         5         1,241           Debt repayments         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common stock for the treasury         (162)         (49)         (331)         (263)           Other         (24)         (15)         (54)         (39)           Cash Used for Financing         (342)         (787)         (394)         (567)           Effect of Exchange Rate Changes on Cash and Cash Equivalents         5         8         (2)         (20)           Change in Cash and Cash Equivalents         (14)         469         3         1,006           Cash and Cash Equivalents - Beginning of		` '	` 4	` 3 <b>0</b>		
Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         Cash dividends paid         (389)         (365)         (748)         (722)           Change in short-term debt         216         (385)         960         (667)           Debt proceeds         —         —         5         1,241           Debt repayments         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common stock for the treasury         (162)         (49)         (331)         (263)           Other         (24)         (15)         (54)         (39)           Cash Used for Financing         (342)         (787)         (394)         (567)           Effect of Exchange Rate Changes on Cash and Cash Equivalents         5         8         (2)         (20)           Change in Cash and Cash Equivalents         (14)         469         3         1,006           Cash and Cash Equivalents - Beginning of Period         320         979         303         442	Investments in time deposits	(292)	(218)	(451)	(323)	
Other         (5)         9         —         10           Cash Used for Investing         (242)         (331)         (487)         (690)           Financing Activities         Cash dividends paid         (389)         (365)         (748)         (722)           Change in short-term debt         216         (385)         960         (667)           Debt proceeds         —         —         5         1,241           Debt repayments         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common stock for the treasury         (162)         (49)         (331)         (263)           Other         (24)         (15)         (54)         (39)           Cash Used for Financing         (342)         (787)         (394)         (567)           Effect of Exchange Rate Changes on Cash and Cash Equivalents         5         8         (2)         (20)           Change in Cash and Cash Equivalents         (14)         469         3         1,006           Cash and Cash Equivalents - Beginning of Period         320         979         303         442	•	` '	` '	` '	` ,	
Financing Activities         Cash dividends paid       (389)       (365)       (748)       (722)         Change in short-term debt       216       (385)       960       (667)         Debt proceeds       —       —       5       1,241         Debt repayments       —       —       (253)       (252)         Proceeds from exercise of stock options       17       27       27       135         Acquisitions of common stock for the treasury       (162)       (49)       (331)       (263)         Other       (24)       (15)       (54)       (39)         Cash Used for Financing       (342)       (787)       (394)       (567)         Effect of Exchange Rate Changes on Cash and Cash Equivalents       5       8       (2)       (20)         Change in Cash and Cash Equivalents       (14)       469       3       1,006         Cash and Cash Equivalents - Beginning of Period       320       979       303       442	·	(5)	9	_	10	
Financing Activities         Cash dividends paid       (389)       (365)       (748)       (722)         Change in short-term debt       216       (385)       960       (667)         Debt proceeds       —       —       5       1,241         Debt repayments       —       —       (253)       (252)         Proceeds from exercise of stock options       17       27       27       135         Acquisitions of common stock for the treasury       (162)       (49)       (331)       (263)         Other       (24)       (15)       (54)       (39)         Cash Used for Financing       (342)       (787)       (394)       (567)         Effect of Exchange Rate Changes on Cash and Cash Equivalents       5       8       (2)       (20)         Change in Cash and Cash Equivalents       (14)       469       3       1,006         Cash and Cash Equivalents - Beginning of Period       320       979       303       442	Cash Used for Investing	(242)	(331)	(487)	(690)	
Cash dividends paid       (389)       (365)       (748)       (722)         Change in short-term debt       216       (385)       960       (667)         Debt proceeds       —       —       5       1,241         Debt repayments       —       —       (253)       (252)         Proceeds from exercise of stock options       17       27       27       135         Acquisitions of common stock for the treasury       (162)       (49)       (331)       (263)         Other       (24)       (15)       (54)       (39)         Cash Used for Financing       (342)       (787)       (394)       (567)         Effect of Exchange Rate Changes on Cash and Cash Equivalents       5       8       (2)       (20)         Change in Cash and Cash Equivalents       (14)       469       3       1,006         Cash and Cash Equivalents - Beginning of Period       320       979       303       442	<del>_</del>					
Change in short-term debt       216       (385)       960       (667)         Debt proceeds       —       —       —       5       1,241         Debt repayments       —       —       (253)       (252)         Proceeds from exercise of stock options       17       27       27       135         Acquisitions of common stock for the treasury       (162)       (49)       (331)       (263)         Other       (24)       (15)       (54)       (39)         Cash Used for Financing       (342)       (787)       (394)       (567)         Effect of Exchange Rate Changes on Cash and Cash Equivalents       5       8       (2)       (20)         Change in Cash and Cash Equivalents       (14)       469       3       1,006         Cash and Cash Equivalents - Beginning of Period       320       979       303       442	•	(389)	(365)	(748)	(722)	
Debt repayments         —         —         (253)         (252)           Proceeds from exercise of stock options         17         27         27         135           Acquisitions of common stock for the treasury         (162)         (49)         (331)         (263)           Other         (24)         (15)         (54)         (39)           Cash Used for Financing         (342)         (787)         (394)         (567)           Effect of Exchange Rate Changes on Cash and Cash Equivalents         5         8         (2)         (20)           Change in Cash and Cash Equivalents         (14)         469         3         1,006           Cash and Cash Equivalents - Beginning of Period         320         979         303         442	Change in short-term debt	`216	(385)		(667)	
Proceeds from exercise of stock options       17       27       27       135         Acquisitions of common stock for the treasury       (162)       (49)       (331)       (263)         Other       (24)       (15)       (54)       (39)         Cash Used for Financing       (342)       (787)       (394)       (567)         Effect of Exchange Rate Changes on Cash and Cash Equivalents       5       8       (2)       (20)         Change in Cash and Cash Equivalents       (14)       469       3       1,006         Cash and Cash Equivalents - Beginning of Period       320       979       303       442	Debt proceeds	_	· <u> </u>	5	1,241	
Acquisitions of common stock for the treasury       (162)       (49)       (331)       (263)         Other       (24)       (15)       (54)       (39)         Cash Used for Financing       (342)       (787)       (394)       (567)         Effect of Exchange Rate Changes on Cash and Cash Equivalents       5       8       (2)       (20)         Change in Cash and Cash Equivalents       (14)       469       3       1,006         Cash and Cash Equivalents - Beginning of Period       320       979       303       442	Debt repayments	_	_	(253)	(252)	
Other         (24)         (15)         (54)         (39)           Cash Used for Financing         (342)         (787)         (394)         (567)           Effect of Exchange Rate Changes on Cash and Cash Equivalents         5         8         (2)         (20)           Change in Cash and Cash Equivalents         (14)         469         3         1,006           Cash and Cash Equivalents - Beginning of Period         320         979         303         442	Proceeds from exercise of stock options	17	27	27	135	
Cash Used for Financing         (342)         (787)         (394)         (567)           Effect of Exchange Rate Changes on Cash and Cash Equivalents         5         8         (2)         (20)           Change in Cash and Cash Equivalents         (14)         469         3         1,006           Cash and Cash Equivalents - Beginning of Period         320         979         303         442	Acquisitions of common stock for the treasury	(162)	(49)	(331)	(263)	
Effect of Exchange Rate Changes on Cash and Cash Equivalents 5 8 (2) (20) Change in Cash and Cash Equivalents (14) 469 3 1,006 Cash and Cash Equivalents - Beginning of Period 320 979 303 442	Other	(24)	(15)	(54)	(39)	
Effect of Exchange Rate Changes on Cash and Cash Equivalents 5 8 (2) (20) Change in Cash and Cash Equivalents (14) 469 3 1,006 Cash and Cash Equivalents - Beginning of Period 320 979 303 442	Cash Used for Financing	(342)	(787)	(394)	(567)	
Change in Cash and Cash Equivalents(14)46931,006Cash and Cash Equivalents - Beginning of Period320979303442	•	5	8	(2)	(20)	
Cash and Cash Equivalents - Beginning of Period 320 979 303 442	·	(14)				
· · · · · · · · · · · · · · · · · · ·	·			303	•	
	, 5 5	\$ 306	\$ 1,448	\$ 306	\$ 1,448	

Unaudited

# KIMBERLY-CLARK CORPORATION SELECTED BUSINESS SEGMENT DATA (Millions)

	Three Mo Jui	nths E ne 30	inded		Six Months Ended June 30				
	 2021		2020	Change		2021		2020	Change
NET SALES	 								
Personal Care	\$ 2,517	\$	2,229	+13 %	\$	4,979	\$	4,651	+7 %
Consumer Tissue	1,424		1,645	-13 %		2,934		3,368	-13 %
K-C Professional	765		724	+6 %		1,517		1,572	-3 %
Corporate & Other	16		14	N.M.		35		30	N.M.

TOTAL NET SALES	\$ 4,722	\$ 4,612	+2 %	\$ 9,465	\$ 9,621	-2 %
OPERATING PROFIT						
Personal Care	\$ 454	\$ 519	-13 %	\$ 935	\$ 1,046	-11 %
Consumer Tissue	196	428	-54 %	465	793	-41 %
K-C Professional	110	155	-29 %	236	336	-30 %
Corporate & Other(a)	(134)	(169)	N.M.	(236)	(324)	N.M.
Other (income) and expense, net(a)	13	8	+63 %	17	22	-23 %
TOTAL OPERATING PROFIT	\$ 613	\$ 925	-34 %	\$ 1,383	\$ 1,829	-24 %

<sup>(</sup>a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including adjustments as indicated in the Non-GAAP Reconciliations.

## PERCENTAGE CHANGE IN NET SALES VERSUS PRIOR YEAR

	Three Months Ended June 30, 2021									
	Acquisition/									
			Net	Mix/	Exited					
	Total <sup>(a)</sup>	Volume	Price	Other	Businesses <sup>(b)</sup>	Currency	Organic <sup>(c)</sup>			
Personal Care	13	4	_	2	4	3	6			
Consumer Tissue	(13)	(15)	_	(1)	_	3	(17)			
K-C Professional	6	(4)	5	1	_	3	2			
TOTAL CONSOLIDATED	2	(4)	1	1	2	3	(3)			

	Six Months Ended June 30, 2021							
	Acquisition/							
			Net	Mix/	Exited			
	Total <sup>(a)</sup>	Volume	Price	Other	Businesses <sup>(b)</sup>	Currency	Organic <sup>(c)</sup>	
Personal Care	7	_	_	2	4	1	2	
Consumer Tissue	(13)	(15)	_	(1)	_	2	(15)	
K-C Professional	(3)	(13)	6	1	_	2	(6)	
TOTAL CONSOLIDATED	(2)	(7)	1	1	2	2	(5)	

- (a) Total may not equal the sum of volume, net price, mix/other, acquisition/exited businesses and currency due to rounding.
- (b) Combined impact of the acquisition of Softex Indonesia and exited businesses in conjunction with the 2018 Global Restructuring Program.
- (c) Combined impact of changes in volume, net price and mix/other.

N.M. - Not Meaningful Unaudited

## KIMBERLY-CLARK CORPORATION NON-GAAP RECONCILIATIONS OUTLOOK FOR 2021

	Estimated Range					
ESTIMATED FULL YEAR 2021 DILUTED EARNINGS PER SHARE						
Adjusted earnings per share	\$	6.65	-	\$	6.90	
Adjustment for charges related to the 2018 Global Restructuring Program		(0.65)	-		(0.40)	_
Per share basis – diluted net income attributable to Kimberly-Clark Corporation	\$	6.00	-	\$	6.50	_

[KMB-F]

Logo - https://mma.prnewswire.com/media/648588/Kimberly Clark RGB Blue Logo.ipg

View original content: https://www.prnewswire.com/news-releases/kimberly-clark-announces-second-quarter-2021-results-301339935.html

SOURCE Kimberly-Clark Corporation

Investor Relations contact: Taryn Miller, 972-281-1318, KC.InvestorRelations@kcc.com, or Media Relations contact: Terry Balluck, 972-281-1397, media.relations@kcc.com